Waystar Considers Sale Amid Market Challenges, Sources Reveal
Healthcare software firm Waystar is exploring a potential sale, two years after its public listing, amidst a broader software sector downturn.
Healthcare software company Waystar is reportedly exploring strategic options, including a potential sale that could see the firm return to private ownership, according to seven sources familiar with the situation. This move comes just two years after Waystar's public listing in New York.
The company, which provides technology solutions for automating and managing administrative tasks in healthcare settings, has engaged investment bank Evercore to guide the process. Currently in its early stages, the exploration of a sale reflects broader market conditions impacting the software sector, with Waystar's market value declining to approximately $4.8 billion following a 24% drop in share price this year.
Investment and Market Dynamics
Waystar's strategic positioning as a healthcare software company rather than a service-oriented business was initially well-received by investors, driving its stock from $20 to a peak of $45 in 2025. However, concerns over technological disruptions, particularly advances in artificial intelligence, have recently pressured the stock, as noted by Morgan Stanley analysts.
The company emerged from a 2017 merger between revenue management firms Zirmed and Navicure. Its major shareholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, who were instrumental in taking Waystar public in 2024. EQT currently holds a 13% stake, with CPPIB and BlackRock Institutional Trust Company holding 10% and 8%, respectively.
Potential Sale and Industry Reactions
The potential sale of Waystar could test the waters for investor interest in the software industry, which has seen a downturn due to macroeconomic factors. While the company has declined to comment on the proceedings, sources indicate that the process remains fluid and may not necessarily result in a sale.
As the company navigates its strategic options, the broader implications for the healthcare software market remain to be seen, especially as technological advancements continue to reshape industry landscapes.